We don't need to change how we subsidise 'breakthrough' cancer treatments
- Written by Richard De Abreu Lourenco, Senior Research Fellow, University of Technology Sydney
Applications to list drugs on the PBS are usually submitted by the manufacturers of those drugs.from shutterstock.comNew therapies that arm the immune system to fight cancer, such as Keytruda (pembrolizumab) and Yervoy (ipilimumab), have offered patients with advanced melanoma real hope of effective treatment.
But until these drugs, known as...
